Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01451606 · ClinicalTrials.gov registry record · Phase 4
Duloxetine for the Treatment of Chronic Pelvic Pain
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT01451606 is a Phase 4 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 34 participants.
The verdict
NCT01451606, a Phase 4 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is examining the effectiveness of duloxetine as a treatment for chronic pelvic pain in women. Duloxetine is FDA approved for the treatment of other pain conditions, including fibromyalgia and diabetic neuropathy.
Interventions
- DRUG Placebo
- DRUG Duloxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-07-11 |
| Est. Completion | 2015-11-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01451606
The ClinicalTrials.gov registry entry for NCT01451606 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01451606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01451606 about?
NCT01451606 is a clinical study titled "Duloxetine for the Treatment of Chronic Pelvic Pain". This study is examining the effectiveness of duloxetine as a treatment for chronic pelvic pain in women. Duloxetine is FDA approved for the treatment of other pain conditions, including fibromyalgia and diabetic neuropathy.
What is the current status of trial NCT01451606?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2011-07-11. Estimated completion is 2015-11-04.
What interventions are being tested in trial NCT01451606?
The interventions under investigation include: Placebo (DRUG), Duloxetine (DRUG).
Who is sponsoring clinical trial NCT01451606?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.